Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCP-erlotinib
- Development stage
- Preclinical
- Lead developer
- Nexus Alliance Biopharmaceuticals
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Oral, Topical
01
Overview
SCP-erlotinib is an investigational small molecule formulation being developed by Nexus Alliance Biopharmaceuticals for the treatment of glioblastoma. The candidate utilizes the company's proprietary **Self-Cycling Polymeric (SCP)** technology to deliver erlotinib, a well-characterized tyrosine kinase inhibitor that targets the **epidermal growth factor receptor (EGFR)**. The SCP platform is designed to enhance the delivery, stability, and bioavailability of the active ingredient, specifically aiming to improve its ability to penetrate the blood-brain barrier and effectively target malignant cells within the central nervous system. By optimizing the pharmacokinetic profile of erlotinib, SCP-erlotinib seeks to address the limitations of conventional EGFR inhibitors in treating primary brain tumors.
- Other names
- erlotinib SCPSCP-formulated erlotinib
02
Targets
Beyond the preview
Go deeper on SCP-erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCP-erlotinib.